Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KROS stock hub

Keros Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KROSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

238.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KROS

In the news

Latest news · KROS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/E5.2

P25 14.9P50 23.2P75 38.5

ROE19.9

P25 -105.6P50 -46.5P75 -3.1

ROIC222.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KROS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

213

Groups with data

Currency

USD

Showing 213 of 213 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001664710
Company name	Keros Therapeutics, Inc.
Country	United States
Country code	US
Cusip	492327101
Employees	78
Employees Change	-91%
Employees Change Percent	-53.85
Enterprise value	$-31.7M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-04-08
Isin	US4923271013
Last refreshed	2026-05-10
Market cap	$238.8M
Market cap category	Micro-Cap
Price	$12.07
Price currency	USD
Rev Per Employee	3,128,987.18x
Sector	Healthcare
Sic	2834
Symbol	KROS
Website	https://www.kerostx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	36.43%
FCF yield	44.36%
P/B ratio	0.78x
P/E ratio	5.25x
P/S ratio	0.98x
PS Forward	109.27x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	28.91%
EBITDA Margin	29.53%
FCF margin	43.41%
Gross margin	47.91%
Gross Profit	$116.9M
Net Income	$87M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Pretax Margin	37.65%
Profit Margin	35.65%
Profit Per Employee	$1.1M
Profitable Years	1
ROA	9.25
Roa5y	-17.57
ROCE	22.22
ROE	19.9
Roe5y	-27.05
ROIC	222.2
Roic5y	-774.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-11.97%
Cagr3y	-35.08%
Cagr5y	-25.65%
EPS Growth Quarters	5
EPS Growth Years	2
Revenue Growth	6,774.96x
Revenue Growth Q	-87.34x
Revenue Growth Years	2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.51
Assets	$338M
Cash	$287.4M
Current Assets	$315.4M
Current Liabilities	$20.4M
Debt	$16.9M
Debt EBITDA	$0.21
Debt Equity	$0.06
Debt FCF	$0.16
Equity	$303.1M
Liabilities	$34.9M
Long Term Assets	$22.6M
Long Term Liabilities	$14.5M
Net Cash	$270.5M
Net Cash By Market Cap	$113
Net Cash Growth	-50%
Net Debt EBITDA	$-3.75
Net Debt Equity	$-0.89
Net Debt FCF	$-2.55
Tangible Book Value	$303.1M
Tangible Book Value Per Share	$15.51
WACC	8.87

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	15.45
Net Working Capital	$10M
Quick ratio	15.1
Working Capital	$295M
Working Capital Turnover	$0.57

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.13%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-11.96%
200-day SMA	15.5
3Y total return	-72.64%
50-day SMA	11.63
50-day SMA vs 200-day SMA	50under200
5Y total return	-77.27%
All Time High	88.8
All Time High Change	-86.41%
All Time High Date	2020-12-08
All Time Low	9.12
All Time Low Change	32.35%
All Time Low Date	2025-04-09
ATR	0.49
Beta	0.95
Beta1y	0.88
Beta2y	0.89
Ch YTD	-40.72
High	12.11
High52	22.55
High52 Date	2025-12-08
High52ch	-46.47%
Low	11.38
Low52	10.42
Low52 Date	2026-03-30
Low52ch	15.89%
Ma50ch	3.83%
Price vs 200-day SMA	-22.14%
RSI	55.99
RSI Monthly	38.1
RSI Weekly	37.74
Sharpe ratio	-0.14x
Sortino ratio	-0.08
Total Return	-1.13%
Tr YTD	-40.72
Tr1m	-1.39%
Tr1w	5.05%
Tr3m	-31.3%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	5
Analyst Price Target Top	$23.4
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.94
Earnings Revenue Estimate	2,400,000x
Earnings Revenue Estimate Growth	-98.86x
Operating Income	$70.6M
Operating margin	28.91
Price target	$21.86
Price Target Change	$81.11
Price Target Change Top	$93.87

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19,187,858%
Float Percent	96.97%
Shares Insiders	3.03%
Shares Institutions	103.2%
Shares Out	19,787,837
Shares Qo Q	-33.05%
Shares Yo Y	1.13%
Short Float	7.3%
Short Ratio	2.81
Short Shares	7.07

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$77.3M
Average Volume	292,272.7x
Bv Per Share	15.51
CAPEX	$-1.6M
Ch1m	-1.39
Ch1w	5.05
Ch1y	-11.96
Ch3m	-31.3
Ch3y	-72.64
Ch5y	-77.27
Ch6m	-25.49
Change	3.69%
Change From Open	4.05
Close	11.64
Days Gap	-0.34
Depreciation Amortization	1,509,000
Dollar Volume	4,762,327.1
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$70.6M
EBITDA	$72.1M
EPS	$2.3
F Score	6
FCF	$106M
FCF EV Yield	-334.32x
FCF Per Share	$5.35
Financing CF	-378,470,000
Fiscal Year End	December
Founded	2,015
Graham Number	28.33137
Graham Upside	134.7
Income Tax	$4.9M
Investing CF	-1,551,000
Ipr	-24.56
Iprfo	-42.11
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-04
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-04
Ma150	15.66
Ma150ch	-22.9%
Ma20	11.52
Ma20ch	4.8%
Net CF	-272,516,000
Next Earnings Date	2026-05-22
Open	11.6
Optionable	Yes
P FCF Ratio	2.25
P OCF Ratio	2.22
Position In Range	94.52
Ppne	21,138,000
Price Date	2026-05-08
Price EBITDA	$3.31
Ptbv Ratio	0.79
Relative Volume	1.35x
Revenue	244,061,000x
SBC By Revenue	11.76x
Share Based Comp	28,696,000
Tax By Revenue	2x
Tax Rate	5.31%
Tr6m	-25.49%
Us State	Massachusetts
Volume	394,559
Z Score	9.88

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KROS pay a dividend?

Capital-return profile for this ticker.

Performance

KROS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KROS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+103.2%

Float: +97.0% of shares outstanding

Insider ownership

+3.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KROS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.0

Neutral momentum band

Price vs 200-day MA

-22.1%

50/200-day relationship not available

Beta (5Y)

0.95

Moves roughly with the market

Sharpe ratio

-0.14

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KROS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KROS stock rating?

Keros Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KROS analysis?

The full report lives at /stocks/KROS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KROS?

The latest report frames KROS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KROS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.